AQST Stock Overview
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally.
Aquestive Therapeutics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$3.30|
|52 Week High||US$7.00|
|52 Week Low||US$3.10|
|1 Month Change||-25.00%|
|3 Month Change||-23.79%|
|1 Year Change||-41.28%|
|3 Year Change||-57.28%|
|5 Year Change||n/a|
|Change since IPO||-79.44%|
Recent News & Updates
Aquestive Therapeutics: Looking To End 2021 On A Bullish Note
Aquestive Therapeutics is moving closer to Libervant’s PDUFA date in December. If approved, Aquestive will finish 2021 on a bullish note that can be sustained into 2022. Aquestive has fought through COVID-19 headwinds and was able to report a strong beat on Q3 with SYMPAZAN continuing to show strong growth over the past 11 consecutive quarters. The company’s AQST-109 epinephrine program reported impressive topline data from a PK study. If approved, AQST-109 could dethrone the EpiPen as the leader in the epinephrine market. I discuss my plans for managing my AQST position ahead of the PDUFA date and potential approval.
|AQST||US Pharmaceuticals||US Market|
Return vs Industry: AQST underperformed the US Pharmaceuticals industry which returned 6.7% over the past year.
Return vs Market: AQST underperformed the US Market which returned 7.7% over the past year.
|AQST Average Weekly Movement||12.8%|
|Pharmaceuticals Industry Average Movement||10.6%|
|Market Average Movement||6.6%|
|10% most volatile stocks in US Market||15.7%|
|10% least volatile stocks in US Market||2.4%|
Stable Share Price: AQST is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: AQST's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis.
Aquestive Therapeutics Fundamentals Summary
|AQST fundamental statistics|
Is AQST overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AQST income statement (TTM)|
|Cost of Revenue||US$14.41m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-1.54|
|Net Profit Margin||-132.11%|
How did AQST perform over the long term?See historical performance and comparison
Is Aquestive Therapeutics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: AQST ($3.3) is trading below our estimate of fair value ($74.5)
Significantly Below Fair Value: AQST is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: AQST is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.
PE vs Market: AQST is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AQST's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AQST has negative assets, so we can't compare its PB Ratio to the US Pharmaceuticals industry average.
How is Aquestive Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AQST is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: AQST is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: AQST's is expected to become profitable in the next 3 years.
Revenue vs Market: AQST's revenue (39.1% per year) is forecast to grow faster than the US market (9.3% per year).
High Growth Revenue: AQST's revenue (39.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AQST's Return on Equity is forecast to be high in 3 years time
How has Aquestive Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AQST is currently unprofitable.
Growing Profit Margin: AQST is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AQST is unprofitable, and losses have increased over the past 5 years at a rate of 18.9% per year.
Accelerating Growth: Unable to compare AQST's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AQST is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.2%).
Return on Equity
High ROE: AQST's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
How is Aquestive Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: AQST has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: AQST has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: AQST has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: AQST's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AQST has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if AQST has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Aquestive Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AQST's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AQST's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AQST's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AQST's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AQST's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Keith Kendall (63 yo)
Mr. Keith J. Kendall has been the Chief Executive Officer of MonoSol RX, Inc since December 17, 2014 and also serves as its President, Principal Accounting Officer, Secretary and Treasurer. Mr. Kendall ser...
CEO Compensation Analysis
Compensation vs Market: Keith's total compensation ($USD1.29M) is above average for companies of similar size in the US market ($USD582.48K).
Compensation vs Earnings: Keith's compensation has been consistent with company performance over the past year.
Experienced Management: AQST's management team is considered experienced (4 years average tenure).
Experienced Board: AQST's board of directors are considered experienced (5.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.5%.
Aquestive Therapeutics, Inc.'s employee growth, exchange listings and data sources
- Name: Aquestive Therapeutics, Inc.
- Ticker: AQST
- Exchange: NasdaqGM
- Founded: 2004
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$132.541m
- Shares outstanding: 40.16m
- Website: https://www.aquestive.com
Number of Employees
- Aquestive Therapeutics, Inc.
- 30 Technology Drive
- New Jersey
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/01/21 00:04|
|End of Day Share Price||2022/01/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.